Real-time Estimate
Cboe BZX
18:05:48 03/05/2024 BST
5-day change
1st Jan Change
2.28
USD
-4.20%
+4.11%
-7.13%
Repro Med Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2000 Growth-Defensive Index
June 25, 2021 at 05:00 am
Repro Med Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 2000 Growth-Defensive Index
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q1 Revenue $8.2M, vs. Street Est of $7.5M
05-01
MT
Transcript : KORU Medical Systems, Inc., Q1 2024 Earnings Call, May 01, 2024
05-01
KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024
05-01
CI
KORU Medical Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-01
CI
Transcript : KORU Medical Systems, Inc., Q4 2023 Earnings Call, Mar 13, 2024
03-13
KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc
03-13
CI
KORU Medical Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-13
CI
KORU Medical Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-13
CI
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q4 Revenue $7.2M, vs. Street Est of $6.9M
03-13
MT
KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024
03-13
CI
KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic
03-11
CI
KORU Medical Systems, Inc. Signs Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for Novel Subcutaneous Immunoglobulin
03-06
CI
Transcript : KORU Medical Systems, Inc. - Analyst/Investor Day
12-05
Transcript : KORU Medical Systems, Inc., Q3 2023 Earnings Call, Nov 08, 2023
11-08
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q3 Revenue $7M, vs. Street Est of $7.9M
11-08
MT
KORU Medical Systems, Inc. Announces Development Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
11-08
CI
KORU Medical Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-08
CI
Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer
11-08
CI
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes
11-07
CI
KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to its Board of Directors
04/10/23
CI
Lake Street Starts Repro Med Systems at Buy
07/09/23
MT
B. Riley Starts Repro Med Systems at Buy With $4.50 Price Target, Says Risk/Reward Becoming More Favorable
07/09/23
MT
Transcript : KORU Medical Systems, Inc., Q2 2023 Earnings Call, Aug 09, 2023
09/08/23
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q2 Revenue $6.9M, vs. Street Est of $7.2M
09/08/23
MT
KORU Medical Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
09/08/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. It is focused on home and specialty infusion solutions. The Companyâs focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patientâs subcutaneous tissues can tolerate and what the system delivers.
More about the company
Last Close Price
2.38
USD
Average target price
3.5
USD
Spread / Average Target
+47.06%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1